Predictors of Chronic Kidney Disease Among Type 2 Diabetic Patients in Assiut University Hospitals (Ckd&dm)

May 5, 2023 updated by: Muhammed Ali Aboalsaud, Assiut University
Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients in Assiut University Hospitals.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Globally, the total number of people with diabetes is estimated to increase from 415 million (8.8%) in 2015 to 642 million (10.4%) in 2040, with the largest alterations expected to occur in the urban population of low- to middle-income countries (LMICs)1. Of them, type 2 diabetes mellitus (T2DM) accounts for more than 90% of people with diabetes2,3. By 2040, the difference worldwide is projected to broaden, with 477.9 million affected people living in urban areas and 163.9 million in rural areas1. It has been postulated that the burden of diabetes and its complications in the LMICs may be contributed by the economic development and rapid urbanisation via increased caloric intake and the adoption of a sedentary lifestyle2,4,5. More importantly, the most striking demo graphic change to diabetes prevalence in global terms also seems to be related to the growth of the proportion of the elderly population6. Despite rates of diabetes-related complications such as CVDs decreasing significantly in the past two decades, it has not translated nearly as well as kidney complications7. Approximately 10% of deaths in people with T2DM are attributable to kidney failure8. It is well-established that diabetes-related chronic kidney disease (CKD) is the leading cause of end-stage kidney disease (ESKD) in T2DM patients worldwide9,10.

In our study, we aim to identify and classify patients attending diabetic outpatient clinic with both CKD and

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Peter At Munir
  • Phone Number: 01553529181

Study Locations

  • Egypt
      • Assiut, Egypt, 088
        • Recruiting
        • Assiut
        • Contact:
          • Peter At Munir
          • Phone Number: 01553529181
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All type 2 diabetic &ckd patient older than 18 years

Description

Inclusion Criteria:

- Patients with T2DM aged 18 years or older. For patients whom eGFR values < or =60 ml/min/1.73m2.

Patient with type 2 DM and ESRD on regular HD with duration less than 1 year

Exclusion Criteria:

Having kidney transplantation incomplete data on glycemic control. Patients with type 2 DM and ESRD on regular HD with duration more than 1 year. Pregnant woman. Patients with advanced comorbides(cardiac, hepatic,

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
CKD patients with T2DM on regular HD
CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD on regular HD at dialysis unit of Assuit University Hospital
CKD patients with T2DM not on regular HD
CKD patients with T2DM attending Assuit university diabetic outpatients clinic and ESRD not on regular HD at dialysis unit of Assuit University Hospital

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
predictors of CKD among T2DM patients attending Assiut University Hospitals. To classify our patients into stages according to KDIGO guidelines
Time Frame: 3 years

To identify predictors of CKD among T2DM patients attending Assiut University Hospitals.

To classify our patients into stages according to KDIGO guidelines
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the possible risk factors contributing to progessing CKD in T2DM patients.
Time Frame: 3 years
To identify the possible risk factors contributing to progessing CKD in T2DM patients.
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Principal Investigator: Muhammed Al Abualsaud, Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 1, 2024

Primary Completion (Anticipated)

March 28, 2024

Study Completion (Anticipated)

April 1, 2024

Study Registration Dates

First Submitted

April 27, 2023

First Submitted That Met QC Criteria

May 5, 2023

First Posted (Estimate)

May 8, 2023

Study Record Updates

Last Update Posted (Estimate)

May 8, 2023

Last Update Submitted That Met QC Criteria

May 5, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ckd in tybe 2 dm

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes With Renal Manifestations

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe